VIVUS,INC. (NASDAQ:VVUS) Files An 8-K Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition
On May3, 2017, VIVUS,Inc., or the Company, conducted a conference
call during which members of its senior management team discussed
financial results for the first quarter ended March31, 2017, a
business update and certain other information. A copy of the
transcript of the conference call is furnished herewith as
Exhibit99.1.
The information in this Form8-K and the exhibit attached hereto
shall not be deemed filed for purposes of Section18 of the
Securities Exchange Act of 1934, as amended (the Exchange Act),
or otherwise subject to the liabilities of that Section, or
incorporated by reference into any of the Companys filings under
the Securities Act of 1933, as amended, or the Exchange Act,
except as shall be expressly set forth by specific reference in
any such filing.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits.
|
ExhibitNo. |
|
Description |
|
99.1 |
Transcript of VIVUS,Inc. First Quarter Ended March31, 2017 |
About VIVUS, INC. (NASDAQ:VVUS)
VIVUS, Inc. is a biopharmaceutical company. The Company operates in the development and commercialization of therapeutic products segment. It provides over two therapies approved by the Food and Drug Association (FDA), which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA (avanafil) for erectile dysfunction (ED). The Company has completed the Phase II studies of Qsymia for the indication of Obstructive Sleep Apnea (OSA) and diabetes. Its Qsymia is available in over 40,000 certified retail pharmacies across the country. Its STENDRA is also approved by the European Commission (EC), under the name, SPEDRA, for the treatment of ED in the Europe. The United States Food and Drug Association approved a Supplemental New Drug Application (sNDA) for STENDRA. STENDRA is indicated to be taken approximately 15 minutes before sexual activity. VIVUS, INC. (NASDAQ:VVUS) Recent Trading Information
VIVUS, INC. (NASDAQ:VVUS) closed its last trading session down -0.02 at 1.02 with 858,342 shares trading hands.
